Glomerular hemodynamics in severe obesity

American Journal of Physiology - Renal Physiology - Tập 278 Số 5 - Trang F817-F822 - 2000
Avry Chagnac1, Talia Weinstein1, Asher Korzets1, Edward Ramadan2, Judith Hirsch1, Uzi Gafter1
1Department of Nephrology and
2Department of Surgery A, Rabin Medical Center-Golda (Hasharon) Campus, Petah Tikva 49372, Israel; and

Tóm tắt

Differential solute clearances were used to characterize glomerular function in 12 nondiabetic subjects with severe obesity (body mass index >38). Nine healthy subjects served as the control group. In the obese group, glomerular filtration rate (GFR) and renal plasma flow (RPF) exceeded the control value by 51 and 31%, respectively. Consequently, filtration fraction increased. The augmented RPF suggested a state of renal vasodilatation involving, mainly or solely, the afferent arteriole. Albumin excretion rate and fractional albumin clearance increased by 89 and 78%, respectively. Oral glucose tolerance tests were suggestive of insulin resistance. Insulin resistance was positively correlated with GFR ( r = 0.88, P < 0.001) and RPF ( r = 0.72, P < 0.001). Mean arterial pressure was higher than in the control group. Fractional clearances of dextrans of broad size distribution tended to be lowered. The determinants of the GFR were estimated qualitatively by using a theoretical model of dextran transport through a heteroporous membrane. This analysis suggests that the high GFR in very obese subjects may be the result of an increase in transcapillary hydraulic pressure difference (ΔP). An abnormal transmission of increased arterial pressure to the glomerular capillaries through a dilated afferent arteriole could account for the augmentation in ΔP.

Từ khóa


Tài liệu tham khảo

Arnold MD, 1994, Lab Invest, 70, 156A

10.1152/ajprenal.1997.273.3.F430

10.3109/00365518009095584

Brun C., 1951, J Lab Clin Med, 37, 955

10.1152/ajprenal.1993.264.6.F1052

10.1172/JCI108395

10.1016/S0006-3495(75)85863-2

10.1152/ajprenal.1985.249.3.F374

Deen WM, 1972, Am J Physiol, 223, 1178, 10.1152/ajplegacy.1972.223.5.1178

10.1161/01.HYP.28.1.127

10.1152/ajprenal.1994.266.1.F1

10.1172/JCI117435

10.1152/ajprenal.1995.268.4.F736

10.1161/01.HYP.23.3.381

10.1161/01.HYP.22.3.292

10.1038/ki.1997.207

10.1172/JCI116792

10.1159/000166902

Metcalf P, 1992, Clin Chem, 38, 1802, 10.1093/clinchem/38.9.1802

10.1038/ki.1995.246

10.1172/JCI115335

10.1002/ar.1092320205

O'Donnell MP, 1985, J Lab Clin Med, 106, 605

10.1097/00004872-198708000-00002

10.2337/diacare.20.7.1183

10.1161/01.HYP.26.4.610

10.1161/01.HYP.13.6.922

10.3181/00379727-74-17827

10.1038/ki.1992.400

Valensi P, 1996, Int J Obes Relat Metab Disord, 20, 574